Figure 3

Kaplan–Meier estimates of the 5-year local recurrence (A), disease-free survival (B), and overall survival (C), by cortactin status. Cortactin overexpressors had significantly lower disease-free and lower survival rates than nonoverexpressors. Additionally, cortactin overexpressors had higher local recurrence rates than nonoverexpressors. Kaplan–Meier estimates of the 5-year overall survival by both EGFR and cortactin status (D).